These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22353234)

  • 21. Comparative efficacy and safety of multiple antiplatelet therapies for secondary prevention of ischemic stroke or transient ischemic attack: A network meta-analysis.
    Xiang RW; Han RB; Yang JY; Zhao MY; Zhao QC; Chen HS; Zhao FQ; Sun ZY; Zhao T; Song TY
    J Neurol Sci; 2019 Apr; 399():199-206. PubMed ID: 30849580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons.
    Huang HP; Lin WH; Chen SG; Chen LZ; Chen MY; Che CH
    Mol Neurobiol; 2017 Mar; 54(2):1456-1466. PubMed ID: 26846361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cilostazol research in Asia: can it be applied to European and American patients?
    Kim JS; Kwon SU; Uchiyama S
    Int J Stroke; 2015 Mar; 10 Suppl 1():1-9. PubMed ID: 25736819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
    Weber R; Weimar C; Diener HC
    Hamostaseologie; 2009 Nov; 29(4):326-33. PubMed ID: 19882077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
    Shinohara Y; Gotoh F; Tohgi H; Hirai S; Terashi A; Fukuuchi Y; Otomo E; Itoh E; Matsuda T; Sawada T; Yamaguchi T; Nishimaru K; Ohashi Y
    Cerebrovasc Dis; 2008; 26(1):63-70. PubMed ID: 18511873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
    Qian Y; Bi Q
    Eur J Med Res; 2013 Dec; 18(1):53. PubMed ID: 24313983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
    Kamal AK; Naqvi I; Husain MR; Khealani BA
    Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD008076. PubMed ID: 21249700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
    Jeng JS; Sun Y; Lee JT; Lin RT; Chen CH; Po HL; Lin HJ; Liu CH; Sun MH; Sun MC; Chern CM; Lien LM; Chiu HC; Hu HH; Chiou HY; Chen ST; Ma H; Hsu CY;
    Int J Stroke; 2015 Jan; 10(1):123-7. PubMed ID: 25394855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MATCH results: implications for the internist.
    Lutsep HL
    Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
    Guthrie R
    Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of cilostazol in percutaneous coronary interventions.
    Rogers KC; Faircloth JM; Finks SW
    Ann Pharmacother; 2012 Jun; 46(6):839-50. PubMed ID: 22669796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
    Lin MP; Meschia JF; Gopal N; Barrett KM; Ross OA; Ertekin-Taner N; Brott TG
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105581. PubMed ID: 33388632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet drugs for ischemic stroke prevention.
    Leys D; Balucani C; Cordonnier C
    Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
    Shinohara Y; Katayama Y; Uchiyama S; Yamaguchi T; Handa S; Matsuoka K; Ohashi Y; Tanahashi N; Yamamoto H; Genka C; Kitagawa Y; Kusuoka H; Nishimaru K; Tsushima M; Koretsune Y; Sawada T; Hamada C;
    Lancet Neurol; 2010 Oct; 9(10):959-68. PubMed ID: 20833591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
    Guo JJ; Xu E; Lin QY; Zeng GL; Xie HF
    Neurosci Bull; 2009 Dec; 25(6):383-90. PubMed ID: 19927175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.